



DOCKET NO.: A0848.70005US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Silence et al.
Serial No.: 10/534,348
Confirmation No.: 4929
Filed: May 9, 2005
For: SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST
TUMOR NECROSIS FACTOR ALPHA AND USES
THEREFOR
Examiner: Gregory S. Emch
Art Unit: 1649

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 28, 2008

Signature: _____

(Michelle M. Quinn)

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION AND SPECIES ELECTION REQUIREMENTS

Sir:

Applicant gratefully acknowledges the Examiner's willingness to discuss the restriction and species election requirements by telephone on January 30, 2008, and thanks the Examiner for extending that courtesy to Applicant's representative. The discussion involved the requirement to elect certain sequences and the lack of inclusion of all of the possible sequences in the invention groups set forth in the restriction requirement mailed August 28, 2007.

The restriction requirement mailed August 28, 2007 listed only sequences of polypeptides comprising an anti-TNF-alpha single domain antibody and a single domain antibody directed against a serum protein (SEQ ID NOs: 30-43) and sequences of polypeptides comprising two or more anti-TNF-alpha single domain antibodies (SEQ ID NOs: 73-76). These sequences do not account for the full scope of the claims. For example, claim 1 recites an anti-TNF-alpha polypeptide comprising at least one anti-TNF-alpha single domain antibody. Claim 1 does not require two anti-TNF-alpha single domain antibodies and does not require a single domain